(Q60921048)

12 September 2020

26 January 2021

27 June 2021

Prevention of Lyme disease after tick bites. A cost-effectiveness analysis

3 October 2022

cites work

1 reference

12 December 2020

Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis

1 reference

12 December 2020

Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis.

1 reference

12 December 2020

Utilization and cost of serologic tests for Lyme disease in Maryland

1 reference

12 December 2020

Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis

1 reference

12 December 2020

A cost-of-illness study of Lyme disease in the United States.

1 reference

12 December 2020

Evaluation of costs in rheumatic diseases: a literature review

1 reference

12 December 2020

The cost effectiveness of vaccinating against Lyme disease

1 reference

12 December 2020

Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America

1 reference

12 December 2020

The cost-effectiveness of vaccination against Lyme disease.

1 reference

12 December 2020

Cost-effectiveness analysis of the Lyme disease vaccine

1 reference

12 December 2020

Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001-2002.

1 reference

12 December 2020

Lyme disease--what is the cost for Scotland?

1 reference

12 December 2020

Economic impact of Lyme disease

1 reference

12 December 2020

WHO Guide for standardisation of economic evaluations of immunization programmes

1 reference

12 December 2020

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

12 December 2020

Neuroborreliosis--an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden

1 reference

12 December 2020

Vaccines against Lyme disease: What happened and what lessons can we learn?

1 reference

12 December 2020

A safe and cost-effective approach to treating Lyme cardiac disease in an era of health care reform

1 reference

12 December 2020

Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: a retrospective model analysis

1 reference

12 December 2020

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

1 reference

12 December 2020

CDC estimates 300,000 US cases of Lyme disease annually

1 reference

12 December 2020

Comparative cost-effectiveness of two-tiered testing strategies for serodiagnosis of lyme disease with noncutaneous manifestations

1 reference

12 December 2020

Empiric antibiotic treatment of erythema migrans-like skin lesions as a function of geography: a clinical and cost effectiveness modeling study

1 reference

12 December 2020

Initial and long-term costs of patients hospitalized with West Nile virus disease

1 reference

12 December 2020

Lyme disease testing by large commercial laboratories in the United States.

1 reference

12 December 2020

Epidemiology and cost of hospital care for Lyme borreliosis in Germany: lessons from a health care utilization database analysis

1 reference

12 December 2020

Health care costs, utilization and patterns of care following Lyme disease

1 reference

12 December 2020

Epidemiology of Lyme disease

1 reference

12 December 2020

An estimate of Lyme borreliosis incidence in Western Europe†.

1 reference

12 December 2020

Need for a New Lyme Disease Vaccine

1 reference

12 December 2020

The cost of Lyme borreliosis

1 reference

12 December 2020

The potential economic burden of Zika in the continental United States

1 reference

12 December 2020